LOGIN  |  REGISTER
Amneal Pharmaceuticals

Tenet Healthcare to Participate in the UBS Global Healthcare Conference

October 23, 2024 | Last Trade: US$158.09 3.19 -1.98

DALLAS / Oct 23, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at 12:30 p.m. Eastern time.

A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. The replay will be available for 30 days.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page